[pending] BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0199-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
The recalled product
- Product
- BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)
- Brand
- BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: (a): Lot 17232401
- exp 11/2025
- Lot 17240974
- exp 05/2026 (b): Lot 17232401
- exp 05/2026 (c): Lot 17232401
- exp 05/2026
UPCs (3)
- 0368462880302
- 0368462879306
- 0368462878309
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
- ModerateBisoprolol Fumarate and Hydrochlorothiazide Tablets Recalled for Failed Quality Specifications
FDA (Drugs) · 2023-11-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27